Sutro Biopharma Diluted EPS

What does Sutro Biopharma do? Sutro Biopharma Inc. generates revenue through the development and manufacturing of pharmaceutical products, primarily focusing on protein therapeutics for cancer and autoimmune disorders. The company utilizes its XpressCF platform to design cytokine-based immuno-oncology therapeutics, antibody-drug conjugates (ADCs), and bispecific antibodies targeting clinically validated targets. Its product candidates, STRO-001 and STRO-002, are ADCs directed against CD74 for multiple myeloma and non-Hodgkin lymphoma, and folate receptor-alpha for ovarian and endometrial cancers, respectively. These therapeutics are optimized for therapeutic index using the XpressCF Platform's cell-free protein synthesis technology. The company's primary customers are patients with specific cancer types, including those diagnosed with multiple myeloma, non-Hodgkin lymphoma, ovarian cancer, and endometrial cancer. Sutro Biopharma's focus on designing therapeutics with potent modalities, such as ADCs and bispecific antibodies, positions it to address unmet medical needs in oncology and autoimmune treatment. The firm's product pipeline, including STRO-001 and STRO-002, is developed through its integrated platform, targeting clinically validated targets to enhance therapeutic efficacy. Sutro Biopharma Inc. operates in the biopharmaceutical sector, leveraging its XpressCF platform to create novel protein therapeutics. The company's revenue model is based on the successful development and commercialization of its pipeline candidates, with STRO-001 and STRO-002 representing key assets in its portfolio. By focusing on specific cancer targets and optimizing therapeutics for therapeutic index, Sutro aims to deliver innovative treatments for patients with limited options. Sutro Biopharma is one of the most popular companies on Eulerpool.